Dissemination of Mifepristone Medical Abortion Study in Mexico City

On July 19-20, Gynuity and the Secretariat of Health of Mexico City (Secretaría de Salud del Distrito Federal – SSDF) organized a series of meetings to disseminate the results of the first mifepristone medical abortion study conducted in Mexico. The first meeting gathered over 40 SSDF officials to highlight key results and discuss programmatic implications of introducing a combined medical abortion regimen. The second meeting involved over 80 health professionals from the public and private sectors in Mexico. The study results demonstrate that the regimen studied, 200 mg mifepristone followed 1-2 days later by 800 mcg buccal misoprostol, is highly effective and comparable to results published in a U.S. study using the same regimen. The meeting also highlighted the role of mid-level providers, specifically nurses and counselors, in successful method provision.